Regorafenib 13CD3

Regorafenib 13CD3 is a modified version of Regorafenib, an oral medication used to treat certain types of cancer. The drug works by blocking several enzymes that promote the growth of cancer cells, ultimately slowing or stopping their progression. Regorafenib 13CD3 is labeled as a “deuterated” version of the original medication, meaning that it has been chemically modified to replace some of the hydrogen atoms with deuterium atoms. This alteration can have several benefits, including increased stability and an extended half-life, which can lead to a longer-lasting and more effective treatment. The chemical formula for Regorafenib 13CD3 is C21H11ClF4N4O3D3, and it has a molecular weight of 482.90 g/mol. It is typically administered orally in tablet form and is rapidly absorbed into the bloodstream, with peak plasma concentrations occurring within 3-4 hours of ingestion. While Regorafenib 13CD3 has been shown to be effective in treating certain types of cancer, it can also cause side effects such as fatigue, diarrhea, and hypertension. Patients considering treatment with this medication should discuss the potential benefits and risks with their healthcare provider, and should be monitored closely for any adverse effects. Overall, Regorafenib 13CD3 is a powerful tool in the fight against cancer, and its unique chemical structure may offer additional benefits to patients in need of treatment.